Analysis on the Pricing and Reimbursement Strategy of Orphan Drugs in Typical European Countries and Its Enlighten-ment to China
- VernacularTitle:欧洲典型国家孤儿药定价和报销策略分析及对我国的启示
- Author:
Yifan YANG
1
;
Jinping XIE
;
Liyu YAN
;
Tingting WENG
;
Rong SHAO
Author Information
1. 中国药科大学国家药物政策与医药产业经济研究中心 南京 211198
- Keywords:
rare disease;
orphan drug;
pricing and reimbursement;
Europe;
health technology assessment
- From:
Chinese Health Economics
2024;43(2):92-96
- CountryChina
- Language:Chinese
-
Abstract:
The pricing and reimbursement of orphan drugs are related to the accessibility of patients,and are of great significance to the prevention and guarantee of rare diseases.European countries have formed special standards and paths for health technology evaluation,and established special payment funds and diversified risk-sharing agreements,which have effectively improved the accessibility of orphan drugs.Based on this,it selected typical European countries to compare the orphan drug pricing and reimbursement methods.Then,it put forward some suggestions"building orphan drug health technology evaluation accelerated program,exploring the health of orphan drug classification security mechanism,and attaining supply incentives and development incentives through orphan drug pricing and adjustment",to optimize the basis for the orphan drug market access mechanism to provide reference.
